Pharmaceutical firm Canbex, a spin-out of University College London, has received a grant for £1.25m ($1.77m) from the TSB Biocatalyst Fund. The injection of cash from the fund, a joint venture between the UK’s Medical Research Council and Technology Strategy Board to support British life sciences, will be used to support the ongoing development of…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
